JPH4
gene geneOn this page
Also known as KIAA1831JP4
Summary
JPH4 (junctophilin 4, HGNC:20156) is a protein-coding gene on chromosome 14q11.2, encoding Junctophilin-4 (Q96JJ6). Junctophilins contribute to the formation of junctional membrane complexes (JMCs) which link the plasma membrane with the endoplasmic or sarcoplasmic reticulum in excitable cells.
This gene encodes a member of the junctophilin family of transmembrane proteins that are involved in the formation of the junctional membrane complexes between the plasma membrane and the endoplasmic/sarcoplasmic reticulum in excitable cells. The encoded protein contains a conserved N-terminal repeat region called the membrane occupation and recognition nexus sequence that is found in other members of the junctophilin family. Alternative splicing results in multiple transcript variants.
Source: NCBI Gene 84502 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 74 total
- MANE Select transcript:
NM_001146028
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:20156 |
| Approved symbol | JPH4 |
| Name | junctophilin 4 |
| Location | 14q11.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | KIAA1831, JP4 |
| Ensembl gene | ENSG00000092051 |
| Ensembl biotype | protein_coding |
| OMIM | 619863 |
| Entrez | 84502 |
Gene structure
Transcript identifiers
Ensembl transcripts: 9 — 8 protein_coding, 1 retained_intron
ENST00000356300, ENST00000397118, ENST00000544177, ENST00000553505, ENST00000927987, ENST00000927988, ENST00000927989, ENST00000927990, ENST00000970525
RefSeq mRNA: 2 — MANE Select: NM_001146028
NM_001146028, NM_032452
CCDS: CCDS9603
Canonical transcript exons
ENST00000356300 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000940680 | 23575685 | 23576456 |
| ENSE00000940681 | 23571802 | 23571920 |
| ENSE00000940682 | 23570928 | 23571460 |
| ENSE00001424689 | 23578180 | 23578790 |
| ENSE00001527341 | 23568038 | 23569717 |
| ENSE00003660716 | 23577075 | 23577624 |
Expression profiles
Bgee: expression breadth ubiquitous, 127 present calls, max score 98.25.
FANTOM5 (CAGE): breadth broad, TPM avg 15.3704 / max 722.3062, expressed in 424 samples.
FANTOM5 promoters (22 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 142513 | 10.0213 | 354 |
| 142506 | 0.8080 | 98 |
| 142512 | 0.5748 | 110 |
| 142503 | 0.5195 | 215 |
| 142501 | 0.4244 | 137 |
| 142511 | 0.3793 | 91 |
| 142515 | 0.3657 | 107 |
| 142508 | 0.3314 | 79 |
| 142516 | 0.3293 | 112 |
| 142510 | 0.2713 | 79 |
Top tissues by expression
130 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| superior frontal gyrus | UBERON:0002661 | 98.25 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 98.12 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 97.82 | gold quality |
| cerebellar cortex | UBERON:0002129 | 97.81 | gold quality |
| cerebellum | UBERON:0002037 | 97.80 | gold quality |
| right frontal lobe | UBERON:0002810 | 97.70 | gold quality |
| nucleus accumbens | UBERON:0001882 | 97.54 | gold quality |
| cortical plate | UBERON:0005343 | 97.51 | gold quality |
| frontal cortex | UBERON:0001870 | 97.33 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 97.23 | gold quality |
| temporal lobe | UBERON:0001871 | 97.19 | gold quality |
| amygdala | UBERON:0001876 | 97.17 | gold quality |
| primary visual cortex | UBERON:0002436 | 97.16 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 97.05 | gold quality |
| prefrontal cortex | UBERON:0000451 | 97.03 | gold quality |
| cerebral cortex | UBERON:0000956 | 96.99 | gold quality |
| Ammon’s horn | UBERON:0001954 | 96.96 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 96.88 | gold quality |
| putamen | UBERON:0001874 | 96.46 | gold quality |
| caudate nucleus | UBERON:0001873 | 96.43 | gold quality |
| brain | UBERON:0000955 | 96.00 | gold quality |
| hypothalamus | UBERON:0001898 | 94.25 | gold quality |
| pituitary gland | UBERON:0000007 | 93.32 | gold quality |
| adenohypophysis | UBERON:0002196 | 91.54 | gold quality |
| substantia nigra | UBERON:0002038 | 88.23 | gold quality |
| body of uterus | UBERON:0009853 | 86.83 | gold quality |
| myometrium | UBERON:0001296 | 85.03 | gold quality |
| ganglionic eminence | UBERON:0004023 | 84.96 | gold quality |
| left uterine tube | UBERON:0001303 | 84.66 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 81.55 | gold quality |
Single-cell (SCXA)
Detected in 5 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-137537 | yes | 1088.62 |
| E-HCAD-13 | yes | 20.63 |
| E-MTAB-7316 | yes | 18.22 |
| E-MTAB-7303 | no | 80.66 |
| E-ANND-3 | no | 2.21 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
139 targeting JPH4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4747-5P | 100.00 | 67.90 | 2681 |
| HSA-MIR-5196-5P | 100.00 | 67.98 | 2761 |
| HSA-MIR-518D-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-518E-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-518F-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-519A-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-519B-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-519C-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-520C-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-522-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-523-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-526A-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-30A-5P | 100.00 | 76.31 | 3233 |
| HSA-MIR-30B-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30C-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30D-5P | 100.00 | 76.32 | 3233 |
| HSA-MIR-30E-5P | 100.00 | 76.32 | 3242 |
| HSA-MIR-6133 | 100.00 | 66.48 | 2064 |
| HSA-MIR-4510 | 100.00 | 66.60 | 2050 |
| HSA-MIR-6127 | 100.00 | 66.76 | 2188 |
| HSA-MIR-6129 | 100.00 | 66.46 | 2080 |
| HSA-MIR-6130 | 100.00 | 66.69 | 2012 |
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-6876-5P | 100.00 | 67.68 | 2126 |
| HSA-MIR-4533 | 100.00 | 69.48 | 2758 |
| HSA-MIR-6870-5P | 99.99 | 68.55 | 2115 |
| HSA-MIR-520G-5P | 99.99 | 66.76 | 658 |
| HSA-MIR-513B-5P | 99.99 | 69.96 | 2150 |
| HSA-MIR-4723-5P | 99.97 | 68.70 | 2034 |
| HSA-MIR-5698 | 99.97 | 68.49 | 2029 |
Literature-anchored findings (GeneRIF, showing 2)
- reports the gene structure of human JPH4 (PMID:14559359)
- reviews the structure and function of human junctophilins (PMID:19095005)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Jph4 | ENSMUSG00000022208 |
| rattus_norvegicus | Ap1g2 | ENSRNOG00000025619 |
| drosophila_melanogaster | jp | FBGN0032129 |
| caenorhabditis_elegans | jph-1 | WBGENE00002179 |
Paralogs (3): JPH1 (ENSG00000104369), JPH2 (ENSG00000149596), JPH3 (ENSG00000154118)
Protein
Protein identifiers
Junctophilin-4 — Q96JJ6 (reviewed: Q96JJ6)
Alternative names: Junctophilin-like 1 protein
All UniProt accessions (2): Q96JJ6, F5H1L9
UniProt curated annotations — full annotation on UniProt →
Function. Junctophilins contribute to the formation of junctional membrane complexes (JMCs) which link the plasma membrane with the endoplasmic or sarcoplasmic reticulum in excitable cells. Provides a structural foundation for functional cross-talk between the cell surface and intracellular calcium release channels. JPH4 is brain-specific and appears to have an active role in certain neurons involved in motor coordination and memory.
Subcellular location. Cell membrane. Endoplasmic reticulum membrane.
Domain organisation. The MORN (membrane occupation and recognition nexus) repeats contribute to the plasma membrane binding, possibly by interacting with phospholipids.
Similarity. Belongs to the junctophilin family.
RefSeq proteins (2): NP_001139500, NP_115828 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR003409 | MORN | Repeat |
| IPR017191 | Junctophilin | Family |
Pfam: PF02493
UniProt features (22 total): repeat 8, compositionally biased region 6, region of interest 3, sequence conflict 2, chain 1, topological domain 1, transmembrane region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q96JJ6-F1 | 64.48 | 0.40 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 0 (showing top):
GO Biological Process (8): regulation of cytokine production (GO:0001817), learning (GO:0007612), regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum (GO:0010880), regulation of cardiac muscle contraction by calcium ion signaling (GO:0010882), regulation of synaptic plasticity (GO:0048167), neuromuscular process controlling balance (GO:0050885), calcium ion transport into cytosol (GO:0060402), regulation of store-operated calcium entry (GO:2001256)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (8): endoplasmic reticulum membrane (GO:0005789), smooth endoplasmic reticulum (GO:0005790), plasma membrane (GO:0005886), junctional sarcoplasmic reticulum membrane (GO:0014701), junctional membrane complex (GO:0030314), dendritic shaft (GO:0043198), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| cytokine production | 1 |
| regulation of gene expression | 1 |
| regulation of multicellular organismal process | 1 |
| learning or memory | 1 |
| release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 1 |
| regulation of release of sequestered calcium ion into cytosol | 1 |
| calcium-mediated signaling | 1 |
| regulation of cardiac muscle contraction | 1 |
| cardiac muscle contraction | 1 |
| modulation of chemical synaptic transmission | 1 |
| regulation of biological quality | 1 |
| musculoskeletal movement | 1 |
| neuromuscular process | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| calcium ion transmembrane import into cytosol | 1 |
| store-operated calcium entry | 1 |
| regulation of calcium ion transport | 1 |
| binding | 1 |
| organelle membrane | 1 |
| nuclear outer membrane-endoplasmic reticulum membrane network | 1 |
| endoplasmic reticulum subcompartment | 1 |
| endoplasmic reticulum | 1 |
| membrane | 1 |
| cell periphery | 1 |
| sarcoplasmic reticulum membrane | 1 |
| sarcoplasm | 1 |
| protein-containing complex | 1 |
| dendrite | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
1940 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| JPH4 | CACNA1S | Q13698 | 822 |
| JPH4 | ASPH | Q12797 | 776 |
| JPH4 | SYPL2 | Q5VXT5 | 752 |
| JPH4 | RYR1 | P21817 | 744 |
| JPH4 | TRDN | Q13061 | 741 |
| JPH4 | STIM1 | Q13586 | 727 |
| JPH4 | CACNA1C | Q13936 | 631 |
| JPH4 | CASQ1 | P31415 | 577 |
| JPH4 | CACNA1D | Q01668 | 576 |
| JPH4 | CALM1 | P02593 | 545 |
| JPH4 | CALML4 | Q96GE6 | 527 |
| JPH4 | CALML3 | P27482 | 519 |
| JPH4 | CALML5 | Q9NZT1 | 519 |
| JPH4 | CALML6 | Q8TD86 | 517 |
| JPH4 | STIMATE | Q86TL2 | 506 |
IntAct
11 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| JPH4 | UBQLN1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| JPH4 | UBQLN2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| JPH4 | ZSWIM8 | psi-mi:“MI:0914”(association) | 0.530 |
| JPH4 | ZSWIM8 | psi-mi:“MI:0914”(association) | 0.350 |
| UBQLN1 | JPH4 | psi-mi:“MI:0915”(physical association) | 0.000 |
| UBQLN2 | JPH4 | psi-mi:“MI:0915”(physical association) | 0.000 |
| corE | JPH4 | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (113): ARHGAP29 (Affinity Capture-MS), GCC1 (Affinity Capture-MS), RAD18 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), UACA (Affinity Capture-MS), TRIOBP (Affinity Capture-MS), PPP1R12C (Affinity Capture-MS), MPRIP (Affinity Capture-MS), UBE2O (Affinity Capture-MS), ZSWIM8 (Affinity Capture-MS), CCDC14 (Affinity Capture-MS), IFT74 (Affinity Capture-MS), IFT81 (Affinity Capture-MS), PRRC2B (Affinity Capture-MS), IFT22 (Affinity Capture-MS)
ESM2 similar proteins: A2A288, A6NIX2, A6NLJ0, A6QQ91, B7Z1M9, B7ZBB8, B8ZZ34, D3ZZN9, J3QNX5, O02756, O88671, P0C7L8, P0CG09, P0DKB5, P27539, P37318, Q02779, Q2KJ18, Q2M3V2, Q2MJR0, Q3U0S6, Q4G0M1, Q4VYA0, Q5JR98, Q5T442, Q5U651, Q6GL23, Q6NY19, Q6P6N5, Q6UXK2, Q6ZW31, Q7Z4P5, Q86YV0, Q8BLS7, Q8BRJ4, Q8C013, Q8CII9, Q8N144, Q8NCU7, Q96BM1
Diamond homologs: Q2PS20, Q69FB3, Q80WT0, Q8WXH2, Q96JJ6, Q9BR39, Q9ET77, Q9ET78, Q9ET80, Q9GKY7, Q9GKY8, Q9HDC5
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
74 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 70 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
746 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 14:23571919:CC:C | acceptor_gain | 0.9900 |
| 14:23571920:CC:C | acceptor_gain | 0.9900 |
| 14:23571921:C:CC | acceptor_gain | 0.9900 |
| 14:23577076:T:TA | donor_gain | 0.9900 |
| 14:23571796:CCTCA:C | donor_loss | 0.9800 |
| 14:23571797:CTCA:C | donor_loss | 0.9800 |
| 14:23571798:TCACC:T | donor_loss | 0.9800 |
| 14:23571799:CACC:C | donor_loss | 0.9800 |
| 14:23571800:A:C | donor_loss | 0.9800 |
| 14:23571801:C:T | donor_loss | 0.9800 |
| 14:23571916:CTGCC:C | acceptor_gain | 0.9800 |
| 14:23571918:GCCCT:G | acceptor_loss | 0.9800 |
| 14:23571919:CCCTG:C | acceptor_loss | 0.9800 |
| 14:23571922:T:A | acceptor_loss | 0.9800 |
| 14:23571923:G:C | acceptor_loss | 0.9700 |
| 14:23571925:C:CT | acceptor_gain | 0.9700 |
| 14:23575846:G:A | donor_gain | 0.9700 |
| 14:23577107:T:TA | donor_gain | 0.9700 |
| 14:23575725:CGG:C | donor_gain | 0.9600 |
| 14:23571931:C:CT | acceptor_gain | 0.9500 |
| 14:23572836:C:A | donor_gain | 0.9500 |
| 14:23575679:GCCCA:G | donor_loss | 0.9500 |
| 14:23575680:CCCA:C | donor_loss | 0.9500 |
| 14:23575683:ACCTG:A | donor_loss | 0.9500 |
| 14:23575684:CCTG:C | donor_loss | 0.9500 |
| 14:23576456:CCT:C | acceptor_loss | 0.9500 |
| 14:23576458:T:C | acceptor_loss | 0.9500 |
| 14:23576465:G:T | acceptor_gain | 0.9500 |
| 14:23575767:TA:T | donor_gain | 0.9400 |
| 14:23575768:AA:A | donor_gain | 0.9400 |
AlphaMissense
3972 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 14:23575909:C:A | W309C | 1.000 |
| 14:23575909:C:G | W309C | 1.000 |
| 14:23575911:A:G | W309R | 1.000 |
| 14:23575911:A:T | W309R | 1.000 |
| 14:23575917:C:A | G307C | 1.000 |
| 14:23575917:C:G | G307R | 1.000 |
| 14:23575965:G:T | R291S | 1.000 |
| 14:23575978:C:A | W286C | 1.000 |
| 14:23575978:C:G | W286C | 1.000 |
| 14:23575980:A:G | W286R | 1.000 |
| 14:23575980:A:T | W286R | 1.000 |
| 14:23576251:G:C | F195L | 1.000 |
| 14:23576251:G:T | F195L | 1.000 |
| 14:23576253:A:G | F195L | 1.000 |
| 14:23576437:C:A | W133C | 1.000 |
| 14:23576437:C:G | W133C | 1.000 |
| 14:23576439:A:G | W133R | 1.000 |
| 14:23576439:A:T | W133R | 1.000 |
| 14:23575841:T:C | Y332C | 0.999 |
| 14:23575841:T:G | Y332S | 0.999 |
| 14:23575842:A:C | Y332D | 0.999 |
| 14:23575883:C:T | G318E | 0.999 |
| 14:23575884:C:A | G318W | 0.999 |
| 14:23575889:C:A | G316V | 0.999 |
| 14:23575889:C:T | G316D | 0.999 |
| 14:23575900:G:C | N312K | 0.999 |
| 14:23575900:G:T | N312K | 0.999 |
| 14:23575901:T:A | N312I | 0.999 |
| 14:23575910:C:G | W309S | 0.999 |
| 14:23575916:C:A | G307V | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000130078 (14:23569116 C>A,T), RS1000175614 (14:23569344 G>A), RS1000189645 (14:23572470 G>A), RS1000255769 (14:23569757 A>G,T), RS1000310383 (14:23568726 C>A), RS1000449298 (14:23576704 G>A), RS1000794867 (14:23574131 G>C,T), RS1000858874 (14:23576329 G>A,T), RS1001063730 (14:23574732 T>C), RS1001184676 (14:23574461 C>T), RS1001186641 (14:23570827 G>A,C), RS1001299595 (14:23577732 C>T), RS1001303250 (14:23569495 CAAAG>C), RS1001465066 (14:23577980 G>A), RS1001852651 (14:23578266 C>G)
Disease associations
OMIM: gene MIM:619863 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
25 total (human), top 25 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects cotreatment, increases expression, affects expression, increases methylation | 6 |
| mercuric bromide | decreases expression, affects cotreatment | 2 |
| Phenylmercuric Acetate | affects cotreatment, decreases expression | 2 |
| p-Chloromercuribenzoic Acid | affects cotreatment, decreases expression | 2 |
| propionaldehyde | increases expression | 1 |
| bisphenol A | affects cotreatment, decreases methylation | 1 |
| ethyl-p-hydroxybenzoate | decreases expression | 1 |
| trichostatin A | increases expression | 1 |
| butyraldehyde | increases expression | 1 |
| S-(1,2-dichlorovinyl)cysteine | decreases expression, decreases reaction | 1 |
| pentanal | increases expression | 1 |
| entinostat | increases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, decreases expression, increases expression | 1 |
| abrine | increases expression | 1 |
| dorsomorphin | affects cotreatment, decreases expression, increases expression | 1 |
| licochalcone B | increases expression | 1 |
| Fulvestrant | affects cotreatment, decreases methylation | 1 |
| Aldehydes | increases expression | 1 |
| Benzo(a)pyrene | decreases methylation, increases methylation | 1 |
| Lipopolysaccharides | decreases expression, decreases reaction | 1 |
| Niclosamide | increases expression | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Tretinoin | decreases expression | 1 |
| Urethane | increases expression | 1 |
| Acrylamide | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.